Aurolife is part of a group of companies that has a long history of excelling in generic pharmaceutical product development, manufacturing and marketing. The support and expertise of our parent organization has given Aurolife a jump start in building a solid pharmaceutical portfolio very quickly. The Aurolife family consists of an experienced management team with expertise in manufacturing, R&D, Quality Assurance and Quality control, finance and regulatory affairs.
Aurolife has 100,000 square feet state-of-the-art US FDA approved cGMP compliant manufacturing facility with an investment of over US $50 million. The facility also has special infrastructure to comply with DEA guidelines enabling us to manufacture controlled substances. The facility, as it becomes fully equipped, will have the capacity to manufacture up to four billion units of tables/capsules annually in both regular and extended release solid dosage formulations. Aurolife is also in the process of constructing a large facility at Dayton, New Jersey to cater for the storage and distribution of drugs for Aurobindo group of companies in USA.
Aurolife's goal is to become the leading US based generic pharmaceutical product manufacturer in the specialty and niche areas drug. Aurolife is targeted to obtain 100+ ANDA submissions, 70+ US FDA approved ANDAs and to manufacture and market 70+ products with 350+ dosage forms by the year 2014.
Aurolife is a 100% owned subsidiary of Aurobindo Pharma USA Inc (APUSA) and is part of $700+ million strong Aurobindo group of companies. Aurobindo Pharma USA has an excellent marketing network in the US and has recorded a scorching pace of growth. The group's flag ship company, Aurobindo Pharma Ltd (APL), is an Indian based, multinational company, with headquarters in Hyderabad, India. APL is an established leader in pharmaceutical R&D, manufacturing, formulations and bulk production. APL markets its products across 100+ countries. Aurolife is exclusively created to address the US pharmaceutical manufacturing needs and to address market opportunities.